InvestorsHub Logo
Followers 1008
Posts 70422
Boards Moderated 4
Alias Born 09/30/2004

Re: None

Tuesday, 01/14/2020 10:53:06 AM

Tuesday, January 14, 2020 10:53:06 AM

Post# of 1726
I added this AM premarket on the pullback. What I love about the news is Bayer is pretty much funding everything and allowing DARE to use their facilities.

Under the agreement, Daré will receive an upfront payment and access to Bayer's extensive clinical and market capabilities while retaining control over Ovaprene's development and regulatory approval process. Bayer receives the right to obtain exclusive rights to commercialize the product in the U.S. following completion of the pivotal clinical trial being undertaken by Daré. If Bayer, in its sole discretion, makes payment to Daré of $20 million, which Daré intends to apply to reimbursement of clinical study costs, then the exclusive license to commercialize Ovaprene in the U.S. will become effective. Daré will also be entitled to receive commercial milestone payments potentially totaling $310 million, in addition to double digit tiered royalties on net sales.



This will be a huge winner once the profit takers are out.
Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent DARE News